Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

The company states: “Novo Nordisk (NVO) announced headline results ... demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo.

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss over 72 weeks with once-weekly 7.2 mg semaglutide and ...

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...